Related Experiment Video
Updated: May 28, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma
Rit Vatsyayan1, Jyotsana Singhal, Lokesh Dalasanur Nagaprashantha
1Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Abstract:
The renal cell carcinoma (RCC) is one of the top 10 cancers in USA. The renal tumors are highly angiogenic and are resistant to conventional interventions, particularly radiotherapy. The advent of multi-specific tyrosine kinase inhibitor sorafenib has improved the progression-free survival in RCC, but overall survival in recurrent and metastatic RCC is still a concern that has lead to characterization of combinatorial regimens. Hence, we studied the effect of combination of nutlin-3, an MDM2 inhibitor, which increases p53 levels, and sorafenib in RCC. Sorafenib along with nutlin-3 synergistically inhibited the cell survival and enhanced caspase-3 cleavage leading to apoptosis in RCC. Nutlin-3 and sorafenib were more effective in reducing the migration of RCC, in combination than as single agents. Sorafenib and nutlin-3 decreased the phosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) and ERK along with inducing p53 activity. The sorafenib and nutlin-3 co-treatment lead to enhanced levels of p53, p-p53, and increase in the levels of p53 pro-apoptotic effector PUMA, Bax, and decrease in the anti-apoptotic Bcl-2 levels. Importantly, our studies revealed that sorafenib alone can activate p53 in a concentration dependent manner. Thus, co-treatment of nutlin-3 with sorafenib leads to increased half-life of p53, which in turn can be activated by sorafenib, to induce downstream pro-apoptotic and anti-proliferative effects. This is the first report showing the synergistic effect of sorafenib and nutlin-3 while providing a strong clinical-translational rationale for further testing of sorafenib and nutlin-3 combinatorial regimen in human RCC.
Insights
Combining nutlin-3, an MDM2 inhibitor, with sorafenib synergistically enhances apoptosis and reduces migration in renal cell carcinoma (RCC). This combination therapy shows promise for treating advanced RCC by increasing p53 activity and downstream pro-apoptotic effects.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Renal cell carcinoma (RCC) is a leading cancer in the USA, characterized by high angiogenesis and resistance to conventional treatments.
- While sorafenib (a tyrosine kinase inhibitor) improves progression-free survival in RCC, overall survival remains a challenge, necessitating combinatorial strategies.
- MDM2 inhibitors, like nutlin-3, increase p53 levels, a key tumor suppressor, offering a potential therapeutic avenue.
Purpose of the Study:
- To investigate the synergistic effects of combining nutlin-3 and sorafenib in renal cell carcinoma (RCC).
- To elucidate the molecular mechanisms underlying the combined efficacy of nutlin-3 and sorafenib in RCC.
- To provide a clinical-translational rationale for testing this combinatorial regimen in human RCC.
Main Methods:
- In vitro studies on RCC cell lines treated with nutlin-3 and/or sorafenib.
- Assessment of cell survival, apoptosis (caspase-3 cleavage), and migration.
- Analysis of key molecular targets including p53, p-p53, VEGFR-2, ERK, PUMA, Bax, and Bcl-2.
- Evaluation of sorafenib's effect on p53 activation.
Main Results:
- Nutlin-3 and sorafenib demonstrated synergistic inhibition of RCC cell survival and enhanced apoptosis.
- The combination therapy significantly reduced RCC cell migration compared to single agents.
- Co-treatment decreased phosphorylation of VEGFR-2 and ERK, while increasing p53 activity, p-p53, PUMA, and Bax, and decreasing Bcl-2.
- Sorafenib alone was found to activate p53 in a concentration-dependent manner.
Conclusions:
- The combination of nutlin-3 and sorafenib exhibits synergistic anti-cancer effects in RCC.
- This combinatorial approach enhances p53 activity and downstream pro-apoptotic signaling, leading to reduced cell survival and migration.
- These findings support the clinical investigation of nutlin-3 and sorafenib as a combinatorial regimen for human RCC treatment.